Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 2 of Tucatinib in Combination with Trastuzumab Deruxtecan

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04539938?term=A+Single+Arm%2C+Open+Label+Phase+2+Study+of+Tucatinib+in+Combination+with+Trastuzumab+Deruxtecan+in+Subjects+with+Previously+Treated+Unresectable+Locally-Advanced+or+Metastatic+HER2%2B+Breast+Cancer&draw=2&rank=1